Shenzhen Kangernuo Biotechnology Co., Ltd. takes the Institute of Microbiology of China Academy of Sciences as the research and development platform, takes the enterprise purpose of prolonging human life and improving the national health level, and is committed to applying biotechnology to research and develop drugs and treatments for major diseases such as cancer and hepatitis B, promoting the market transformation of scientific and technological achievements and making contributions to improving human health level.

The Key Laboratory of Pathogenic Microbes and Immunity College of Institute of Microbiology, China Academy of Sciences is the only research group at home and abroad that uses heat shock protein system to study hepatitis B virus infectious diseases and cancer vaccine development. The related patent "the complex of hepatitis B virus antigen polypeptide and heat shock protein and its application" has been authorized by China (ZL 01KLOC-0/04060.2, 2003), and an international patent application has been submitted, which has been authorized by the United States (PCT/CN0100295, US72477/KLOC). This project is supported by the National 973 Project, 863 Project, major projects of Chinese Academy of Sciences, natural science foundation projects and frontier projects of Institute of Microbiology. , published more than 20 related SCI papers, and the impact factor exceeded 100. Related research results have been obtained by Natue (429 (17): 715, 2004), Nature Reviews Cancer (4: 500-501,2004), PNAS (103 (46).

Shenzhen Kangernuo Biotechnology Co., Ltd. has been authorized by the Institute of Microbiology, China Academy of Sciences, and has the patent of "the complex of hepatitis B virus antigen polypeptide and heat shock protein and its application" (,Meng, Gao Fu, 0 1 1 04060.2, 2003; B2, July 24, 2007). The company cooperates with the Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, China Academy of Sciences to develop therapeutic vaccine products and preparation technologies for treating major diseases such as cancer and hepatitis B. At present, the autologous tumor vaccine we developed has been clinically applied in the Cancer Hospital of China Academy of Medical Sciences and achieved good results.

At present, it is the first in China to carry out clinical treatment for patients with malignant tumors such as liver cancer, breast cancer and digestive tract cancer. Clinical research shows that Ruisen autologous tumor vaccine can effectively delay tumor recurrence, prolong patients' survival time and improve patients' quality of life.